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SUMMARY
In this editorial, we consider the vexing issue of ‘unrelated future costs’ (for example, the costs of caring for people with
dementia or kidney failure after preventing their deaths from a heart attack). The National Institute of Health and Care Ex-
cellence (NICE) guidance is not to take such costs into account in technology appraisals. However, standard appraisal prac-
tice involves modelling the beneﬁts of those unrelated technologies. We argue that there is a sound principled reason for
including both the costs and beneﬁts of unrelated care. Changing this practice would have material consequences for deci-
sions about reimbursing particular technologies, and we urge future research to understand this better. Copyright © 2016
John Wiley & Sons, Ltd.
Received 26 January 2016; Revised 26 April 2016; Accepted 11 May 2016
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1. INTRODUCTION
Health economic evaluation has progressed enormously in the last 20 years, and is now embedded in decision
making in several jurisdictions when evaluating medical technologies (Drummond et al., 2015). However, one
unresolved issue has been that of so-called ‘unrelated future costs’ (UFC), succinctly captured in the NICE
Guide to the Methods of Technology Appraisal (NICE, 2013) which includes the following recommendation:
‘5.5.7 Costs related to the condition of interest and incurred in additional years of life gained as a result of
treatment should be included in the reference-case analysis. Costs that are considered to be unrelated to the
condition or technology of interest should be excluded.’ (authors’ italics)
NICE gives no reasoning, and the reader may surmise that the recommendation in italics is not contentious.
However, this is not the case (Garber and Phelps, 1997; Meltzer, 1997; Nyman, 2004; van Baal et al., 2007;
Lee, 2008; Feenstra et al., 2008). The debate was summarised by Meltzer in a recent contribution that predated
the NICE guidance (Meltzer, 2012). Published objections to the routine inclusion of UFC are that to do so:
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• Involves making assumptions about future care decisions
• Is practically difﬁcult
• Is not material to decision making.
Even more recently, Van Baal and colleagues (2016) have challenged these arguments. Van Baal et al.
(2016) approach the question of whether to include UFC by formulating and conducting a technical analysis
of a two period constrained optimisation model which captures the essential elements of the NICE decision
framework. From that, they conclude that ignoring UFC leads to suboptimal decision rules. The current edito-
rial is complementary to that of van Baal et al. (2016), in that we take a more qualitative, principles-ﬁrst ap-
proach to analysis, which leads us to a similar destination, albeit by a different route. In particular, we
consider the three arguments above under the headings of Principles, Practicalities, and Implications for pa-
tients and the population at large respectively.
2. PRINCIPLES
Drummond et al. (2015) deﬁne economic evaluation as ‘the comparative analysis of alternative courses of ac-
tion in terms of both their costs and consequences’ (p4). It is generally recognised that how these costs and con-
sequences are deﬁned ﬂow from the notion of perspective: for example, from the societal perspective, the value
of carer time should be monetised and included in analysis, whereas from the perspective of the public purse,
the value of carer time should not be included in the analysis.
For the purposes of this discussion we assume the following.
• That the remit of the healthcare system is to maximise health subject to budget constraints on health and
social care spending, suggesting the appropriate perspective is the health and social care budget. While
this frame already incorporates contestable assumptions, it is the default frame for most health eco-
nomic analysis in many jurisdictions and underlies the perspective of NICE’s current reference case.
• Within this remit, in the words of the UK’s overarching guidance on economic appraisal (HM Treasury,
2003), ‘The relevant costs and beneﬁts to government and society of all options should be valued… In
this context, relevant costs and beneﬁts are those that can be affected by the decision at hand’ (p. 19).
Thus, the test for including or excluding a cost or beneﬁt depends on whether it ﬂows from the commit-
ment which we are being asked to make at the moment of decision.
The nub of the issue here is that a commitment to introduce a new technology may introduce a ﬂow of future
needs for healthcare which it may not be possible politically or indeed ethically to deny. However, clearly,
when we make decisions about technologies, we do not know what decisions will be made about future care
—indeed, we may not even know what the care options will be; for example, if we save the life of a 30-year
old in 2015, who knows what the cost of preventing or treating her dementia in 2065 will be? All we can ob-
serve is the current costs of care and the historic beneﬁts of having provided care. Two possible responses to
this uncertainty are: to take a narrow scope of decision, taking the view that in funding current care, we are
not making any commitments about future healthcare treatment; or to take a broad scope of decision,
recognising that we are retaining the option to provide future care and to make some deﬁnite plausible (though
potentially incorrect) modelling assumptions about what future treatment might be (e.g. we assume that the said
30-year-old will experience similar dementia care in 2065 to that which an 80-year-old would receive in 2015).
We highlight this in Figure F11 which shows four options for the handling of unrelated costs and beneﬁts
which ﬂow from future decisions.
Standard practice in economic evaluation (Briggs et al., 2006) often involves using life-tables from clinical
trials, observational studies, or population studies to estimate future beneﬁts. Lifetables describe all-cause mor-
tality and so reﬂect the health beneﬁts which ﬂow from decisions to prevent or treat all health conditions. Ac-
counting for living longer, but excluding UFC, is represented by quadrant 2 of Figure 1 where the beneﬁts of
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treating other conditions on mortality are included, but where UFC are excluded. Such practice contradicts the
light of Treasury Green Book advice, which recommends considering both costs and beneﬁts. Moreover, it is
hard to see why the scenario represented in quadrant 2 should be any more acceptable in principle than the sce-
nario of quadrant 3, which also involves the inconsistent treatment of costs and beneﬁts (this time including
UFC but excluding the beneﬁts).
3. PRACTICALITIES
The analysis of Section 2 suggests that there are two ways to make current practice consistent:
a. Include the costs of future decisions about healthcare (bringing practice from quadrant 2 to quadrant 1)
b. Exclude the beneﬁts of future decisions about healthcare (bringing practice from quadrant 2 to quadrant
4)
We appraise these options from the point of view of practicality. Health economists have developed several
methods to include the costs of future decisions about healthcare (Kruse et al., 2012; Manns et al., 2003;
Meltzer et al., 2000; Van Baal et al., 2011). What these methods have in common is that they implicitly assume
that decisions about future healthcare will be in line with the current standard of care. This has the advantage of
being consistent with the use of survival tables to model beneﬁts, which implicitly assume the current standard
of care (in the sense that the current standard of care is embedded in historical experience reﬂected in the sur-
vival tables).
Of course, life expectancy tends to increase over time, the cost of a given treatment tends to fall over time,
and as costly new treatments become available, the future costs of the future standard of care may differ from
the current costs of the current standard of care. Hence, one means to develop these methods is to try to project
forward the experienced cost and beneﬁt trajectory rather than to model the costs and beneﬁts of future
healthcare decisions based on the current standard of care. Overall, then, we consider option a. (to include
the costs of future decisions) to be a feasible option, while recognising the scope for further development of
methods in this area.
What of the practicality of Option b. (to exclude the beneﬁts of future decisions)? In some settings, e.g.
when offering a life-extending operation to patients with end stage renal disease, where the future decision
may include continuing dialysis or not, excluding the life-prolonging beneﬁts of dialysis would mean assuming
zero residual life expectancy, and so it may be possible and relevant to generate estimates for quadrant 4. In
other settings, however, it is challenging to deﬁne the untreated natural history of disease. Even if the untreated
Figure 1. Options for inclusion/exclusion of costs/beneﬁts
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natural history of the disease is observed, for example in countries where there is little access to medical care,
the data from such countries tends to be poor and people are subject to other hazards (infectious disease, poor
sanitation, conﬂict) which makes it hard, if not impossible, to generalise to richer countries. Thus, option b.
seems less practical in general and perhaps impossible in many settings.
Following the analysis of this section, we conclude that from a practical point of view, including the costs of
future decisions about healthcare is the most promising way to make practice consistent.
4. IMPLICATIONS FOR PATIENTS AND THE POPULATION AT LARGE
Taking into account UFC may or may not change recommendations. In particular, in the case of interventions
which do not materially affect survival (such as alleviating transitory conditions), the resulting change in costs
of future healthcare provision are negligible and may be ignored. However, in cases in which gains from im-
proving health are small compared to gains in survival, the impact may be substantial ( Q2Meltzer, 2007). Thus,
changing practice may change the cost effectiveness ordering of interventions and the funding mix recom-
mended by analysis with regard to subpopulations and conditions. For example, treatments for older popula-
tions with more co-morbidities than younger populations may be relatively disadvantaged by accounting for
UFC. The reasoning is that, in general, the unrelated conditions these groups experience in gained life years
occur sooner following treatment (and therefore would be discounted less) than they would for younger pa-
tients. Treatments for conditions which would otherwise lead to quick and relatively inexpensive deaths (such
as pancreatic cancer) may likewise be disadvantaged.
If one includes the costs and beneﬁts of future unrelated care when assessing a proposed new intervention,
then logically they should also be included in when assessing health opportunity costs. Empirical estimates of a
cost-effectiveness threshold that reﬂects health opportunity costs attempt to capture the health effects of
changes in current expenditure (Claxton et al., 2015a). However, changes in mortality and survival will also
lead to changes in the costs of the system in the future. Given estimates of the costs of unrelated care at older
ages and estimates of where health opportunity costs are likely to fall (by disease area, age and gender)
(Claxton et al., 2015b), it should be possible to assess the implications of such changes in survival and mortal-
ity for the threshold.
5. THE WAY FORWARD
The issue of UFC has been an unresolved issue in economic evaluation for several years. We appreciate and
acknowledge that there is uncertainty about future treatment and its associated costs. Indeed, in many situations
it may be appropriate to perform scenario analyses to investigate how treatment regimes (and associated life
trajectories) may evolve. However, this does not constitute a rationale for excluding UFC, while at the same
time including unrelated future beneﬁts, in an economic evaluation. In our view, those responsible for technol-
ogy appraisal should include the costs of future healthcare decisions in analyses where they may make a ma-
terial difference to results.
Being given permission to include UFC should be a source of relief to analysts. Including ‘related’ but ex-
cluding ‘unrelated’ future costs requires analysts to make judgements about whether particular costs are related
or unrelated. Such judgements may involve deep scientiﬁc and conceptual questions—as one of our anony-
mous reviewers asked, ‘Do we really know enough about a disease like rheumatoid arthritis, for example, or
a childhood autoimmune disorder, to judge which cancers, cardiovascular, mental or musculoskeletal disorders
are entirely unconnected?’
Areas of research also include:
• What is the effect of including UFC on the mix of funded interventions for a representative jurisdiction,
taking into account both changes in the priority ordering of interventions and changes in the cost
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effectiveness threshold? For some conditions and technologies the impact could be substantial: for exam-
ple, relatively inexpensive blood pressure lowering therapies now widely available may make people live
longer only to develop dementia which in the UK has been associated with costs of care substantially
greater than those of cancer or stroke (Luengo-Fernandez et al., 2012).
• What challenges exist in developing costing models to capture UFC? A simple way to model such costs is
to use age-speciﬁc per capita health expenditures but more nuanced and realistic models exist. For exam-
ple, PAID (van Baal et al., 2011) models costs for the Dutch population as depending on both age and
time to death. Developing and validating models the drivers of lifetime healthcare costs for multiple
countries using local large scale linked data sources, building on work such as that of Seshamani and
Gray (2004) and Georghiou et al. (2012), seems an urgent research priority.
We believe that answering these questions will help analysts perform more robust and defensible analyses.
Of course the policy question—of what to fund—remains with decision makers. However, healthcare systems
worldwide will face increasing ﬁscal and demographic stresses in years ahead. When decision makers are faced
with choices which may exacerbate these pressures, the responsibility lies with the analytic community to pro-
vide an accurate accounting of costs and beneﬁts and make the consequences of these choices clear.
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